11 completed, 10 unknown, 4 terminated, 4 withdrawn. 15 Phase 3, 10 Phase 2, 3 Phase 4, 1 Phase 1.
Follow Toremifene: new trials by email Literature Review of Toremifene trials Research Report on Toremifene
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study Aromatase inhibitor, ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist), Tamoxifen - Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 700 | 2023-06-01 | 2023-05-18 | |
| Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) Fluzoparib, Anastrozole, Letrozole - Breast Cancer | Phase 3 | Recruiting | Fudan University | 766 | 2023-06-01 | 2024-02-08 |
| Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene - Breast Cancer, Quality of Life | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 90 | 2022-05-17 | 2026-05-26 |
| Selective Estrogen Modulation and Melatonin in Early COVID-19 Toremifene, Melatonin, Placebo - Covid19 | Phase 2 | Withdrawn | Reena Mehra, MD | 2021-12-01 | 2021-05-10 | |
| Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast Tamoxifen, Toremifene, Anastrozole - Breast Cancer | Unknown | First Hospital of China Medical University | 1354 | 2020-07-01 | 2020-12-14 | |
| Breast Cancer Treatment Based on Organ-like Culture Trastuzumab, Doxorubicin Hydrochloride, Epirubicin hydrochloride - Breast Cancer Organoids | Unknown | Xijing Hospital | 300 | 2019-01-02 | 2019-04-24 | |
| Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Anastrozole, Exemestane, Laboratory Biomarker Analysis - HER2/Neu Negative, Invasive Breast Carcinoma | Phase 4 | Withdrawn | Fred Hutchinson Cancer Center | 2018-09-01 | 2018-12-27 | |
| Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer Tamoxifen, Toremifene - Breast Cancer Female | Phase 3 | Unknown | Chinese Anti-Cancer Association | 844 | 2017-11-01 | 2017-11-22 |
| Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer metformin, Melatonin, Toremifene - Breast Cancer | Phase 2 | Unknown | N.N. Petrov National Medical Research Center of Oncology | 96 | 2015-07-01 | 2019-09-04 |
| Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer Toremifene, Tamoxifen - Breast Cancer | Phase 4 | Completed | Shanghai Jiao Tong University School of Medicine | 104 | 2014-12-01 | 2019-09-24 |
| Estradiol-Receptor Blockade in Older Men and Women Toremifene, Placebo, GHRH/Ghrelin combined Injection - Normal Healthy Volunteers | Phase 1 | Completed | Mayo Clinic | 40 | 2014-12-01 | 2016-09-14 |
| Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Toremifene; Anastrozole - Female Breast Cancer | Phase 4 | Unknown | Peking Union Medical College Hospital | 800 | 2014-11-01 | 2016-12-02 |
| Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea Goserelin, Toremifene - Breast Cancer, Chemotherapy Induced Amenorrhea | Phase 3 | Unknown | Peking Union Medical College Hospital | 300 | 2014-05-01 | 2014-06-04 |
| Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients toremifene or tamoxifen - Breast Cancer Patients in Premenopausal, Estrogen and/or Progesterone Receptor Positive | Phase 2 / Phase 3 | Unknown | Fengxi Su | 3036 | 2014-04-01 | 2014-05-06 |
| Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer Anastrozole, Tamoxifen, Toremifene - Breast Cancer | Phase 3 | Unknown | Peking Union Medical College Hospital | 600 | 2014-03-01 | 2016-05-25 |
| Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets Toremifene - Desmoid Type-fibromatosis | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 25 | 2012-11-01 | 2015-02-02 |
| Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer Toremifene - Risk of Bone Fracture Occurrences | Phase 3 | Withdrawn | GTx | 2011-03-01 | 2013-11-15 | |
| Changes in Breast 3D Ultrasound Measurements Using Toremifene Toremifene - Circulatory; Change | Phase 3 | Completed | Satakunta Central Hospital | 20 | 2010-09-01 | 2011-08-23 |
| Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer Toremifene citrate, Anastrozole - Breast Neoplasms | Phase 2 | Terminated | Japan Breast Cancer Research Network | 240 | 2007-05-01 | 2012-03-30 |
| The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia toremifene, placebo - Breast Pain | Phase 3 | Completed | Satakunta Central Hospital | 10 | 2007-04-01 | 2009-05-13 |
Showing 20 of 31. Sign in to see all of them.
Breast Neoplasms (15) · Carcinoma, Ductal, Breast (3) · Carcinoma, Lobular (3) · Neoplasms, Hormone-Dependent (3) · Prostatic Neoplasms (3) · Desmoid Tumors (2) · Fractures, Bone (2) · Prostatic Intraepithelial Neoplasia (2) · Bone Diseases, Metabolic (1) · Breast Carcinoma In Situ (1) · COVID-19 (1) · Carcinoma, Ovarian Epithelial (1) · Coronavirus Infections (1) · Mastodynia (1) · Neoplasm Metastasis (1)
GTx (4) · Intarcia Therapeutics (4) · Peking Union Medical College Hospital (3) · Satakunta Central Hospital (2) · Advocate Lutheran General Hospital (1) · Chinese Anti-Cancer Association (1) · ETOP IBCSG Partners Foundation (1) · Fengxi Su (1) · First Hospital of China Medical University (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Fred Hutchinson Cancer Center (1) · Fudan University (1) · George Washington University (1) · Japan Breast Cancer Research Network (1) · Joel Nelson, MD (1)
United States (14) · China (10) · Russia (4) · Canada (3) · Ukraine (3) · Finland (2) · Italy (2) · Argentina (1) · Australia (1) · Bulgaria (1) · Japan (1) · Mexico (1) · New Zealand (1) · Romania (1) · Slovenia (1)
Peter Langecker, MD, PhD (2) · Bo Chen, MD (1) · Brian L. Samuels, MD (1) · Chang Gong, docto (1) · Chiara Colombo, MD (1) · Dana Casey, MD (1) · Edda Simoncini, MD (1) · Edith Perez, MD (1) · James D. Ahlgren, MD (1) · Joel B. Nelson, MD (1) · Johannes Veldhuis, MD (1) · Kunwei Shen, Professor (1) · Mitchell Steiner, M.D. (1)
PMID 22245322, PMID 23234631, PMID 23295793, PMID 26602014, PMID 32677982, PMID 41903360
P30CA015704 (1)